Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships for Docetaxel

[1]  Lewis B. Sheiner,et al.  A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[2]  M. O. Karlsson,et al.  The importance of modeling interoccasion variability in population pharmacokinetic analyses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[3]  S. Urien,et al.  Docetaxel serum protein binding with high affinity to alpha1-acid glycoprotein , 2004, Investigational New Drugs.

[4]  M. Aapro,et al.  Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation , 2004, Cancer Chemotherapy and Pharmacology.

[5]  N H Holford,et al.  Simulation of clinical trials. , 2000, Annual review of pharmacology and toxicology.

[6]  L B Sheiner,et al.  Pharmacokinetic/pharmacodynamic modeling in drug development. , 2000, Annual review of pharmacology and toxicology.

[7]  P. Fumoleau,et al.  The cycle-to-cycle variability of docetaxel pharmacokinetics (PK) assessed by population PK analysis , 1999 .

[8]  M. Ratain.  Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L B Sheiner,et al.  Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Verweij,et al.  Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  Alain Mallet,et al.  Optimal design in random-effects regression models , 1997 .

[12]  H. Gurney,et al.  Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  L. Winterbottom,et al.  Response to dexamethasone in patients with fluid retention after docetaxel , 1996, The Lancet.

[14]  G. de Sousa,et al.  Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. , 1996, Cancer research.

[15]  R Temple.  The clinical investigation of drugs for use by the elderly: Food and Drug guidelines , 1987, Clinical pharmacology and therapeutics.

[16]  L B Sheiner,et al.  Premarketing observational studies of population pharmacokinetics of new drugs , 1985, Clinical pharmacology and therapeutics.